Jeffrey Derek Blaney

US Patent:

8637526, Jan 28, 2014

Filed:

May 2, 2011

Appl. No.:

13/099179

Inventors:

Jeffrey Blaney - Piedmont CA, US
Paul A. Gibbons - San Francisco CA, US
Emily Hanan - Redwood City CA, US
Joseph P. Lyssikatos - Piedmont CA, US
Steven R. Magnuson - Dublin CA, US
Richard Pastor - San Francisco CA, US
Thomas E. Rawson - Mountain View CA, US
Aihe Zhou - San Jose CA, US
Bing-Yan Zhu - Palo-Alto CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A01N 43/90
A61K 31/519
C07D 487/00

US Classification:

5142593, 544281

Abstract:

The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R, R, Rand Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

US Patent:

20080200512, Aug 21, 2008

Filed:

Feb 14, 2008

Appl. No.:

12/070027

Inventors:

Jeffrey Mark Blaney - Piedmont CA, US
Normand Hebert - Encinitas CA, US
Stephanie Ann Hopkins - Poway CA, US
Elizabeth A. Jefferson - La Jolla CA, US
Masaki Tomimoto - Osaka, JP

International Classification:

A61K 31/445
C07D 211/60
A61P 31/12

US Classification:

514330, 546226

Abstract:

The invention provides a compound of formula:and methods for making and using the same, where Rand Rare independently hydrogen, Calkyl or Chaloalkyl; Ris hydrogen, halogen, Calkyl or Calkoxy; Ris hydrogen or halogen; and Ris a mono- or di-amino acid moiety, a succinic acid moiety, a urea moiety, or a derivative thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, and methods for making and using the same.

US Patent:

61911062, Feb 20, 2001

Filed:

Mar 20, 1996

Appl. No.:

8/619032

Inventors:

Guy T. Mullenbach - San Francisco CA
Jeffrey M. Blaney - Oakland CA
Steven Rosenberg - Oakland CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12N 1518
C07K 14485
A61K 3818

US Classification:

514 12

Abstract:

EGF muteins in which the histidine at position 16 is replaced with a neutral or acidic amino acid exhibit activity at pHs lower than obtainable with wild type EGF.

US Patent:

56803311, Oct 21, 1997

Filed:

Aug 15, 1994

Appl. No.:

8/290445

Inventors:

Jeffrey M. Blaney - Oakland CA
Michael A. Siani - Oakland CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

G06G 748

US Classification:

364578

Abstract:

A method for generating multiple mimics of an active site of a molecule, such as a protein, using computer modeling of the active site. A putative active site is identified, and the amino acids, or residues, purportedly responsible for the biological activity in question are located. These are represented as virtual residues in a model of the active site. The method generates many different possible representations of the active site of the selected protein, presenting the user with a choice of premodeled molecules for synthesis and testing as a substitute for the protein.

US Patent:

55479359, Aug 20, 1996

Filed:

Aug 2, 1994

Appl. No.:

8/284923

Inventors:

Guy T. Mullenbach - San Francisco CA
Jeffrey M. Blaney - Oakland CA
Steven Rosenberg - Oakland CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12N 1518
A61K 3818
C07K 14485

US Classification:

514 12

Abstract:

EGF muteins in which the histidine at position 16 is replaced with a neutral or acidic amino acid exhibit activity at pHs lower than obtainable with wild type EGF.

US Patent:

57141428, Feb 3, 1998

Filed:

Jun 13, 1996

Appl. No.:

8/664372

Inventors:

Jeffrey M. Blaney - Oakland CA
Fred Cohen - San Francisco CA

International Classification:

A61K 4748

US Classification:

424 852

Abstract:

Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiiodothyroacetic acid, 2,4,6-triiodophenol, flufenamic acid, or the like.